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ABSTRACT 
In this report, we described a rare case of Mycobacterium abscessus subsp. bolletii 
keratitis in a young healthy male, in the absence of risk factors. 
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INTRODUCTION
Nontuberculous mycobacteria (NTM) are ubiquitous environmental 
microorganisms that can be recovered from environmental sources (soil, water) 
and are often found in man-made reservoirs1. These are pathogens that have the 
ability to form biofilms on organic and inorganic materials due to their resistance 
to disinfectants, antibiotics and heavy metals1. 
The NTM can colonize, infect, cause disease, and are therefore, considered 
opportunistic pathogens that can cause disease when associated with risk factors, 
such as accidental or surgical trauma, ocular surface diseases, use of contact lenses, 
or immunosuppression1-4. They are divided into two major groups: 1) slow-growing 
NTM and 2) rapidly-growing NTM1,5. 
Clinically, the most important slow-growing NTM are: Mycobacterium avium 
complex, Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium 
malmoense, Mycobacterium haemophilum, Mycobacterium genavense, 
Mycobacterium marinum, Mycobacterium szulgai, and Mycobacterium 
scrofulaceum. The most important rapidly-growing NTM are: Mycobacterium 
chelonae complex, Mycobacterium fortuitum complex, Mycobacterium abscessus 
(M. abscessus) and its subspecies1,5. 
Some of the M. abscessus subspecies, such as M. abscessus subsp. abscessus, 
M. abscessus subsp. bolletii, and M. abscessus subsp. massiliense have been 
responsible for a wide variety of skin, soft tissue, ocular, and other serious infections, 
including widespread disease1. We report a rare case of Mycobacterium abscessus 
subsp. bolletii keratitis in a young healthy male, in the absence of risk factors.
 
CASE REPORT
A 37-year-old healthy male, who works as an industrial plumber, born and living 
in of Belo Oriente, Minas Gerais State, Brazil, visited the emergency department 
of Sao Geraldo Hospital, Federal University of Minas Gerais reporting an insidious 
hyperemia, intense photophobia and pain in the left eye for about 30 days. The 
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patient reported no trauma, ocular foreign body, previous 
eye surgery, or use of contact lenses. He confirmed the 
appropriate use of personal protective equipment. During 
this period, he sought medical care at another service, and 
was medicated with retinol acetate eye ointment, amino 
acids, methionine and chloramphenicol (Regencel®), 
followed by topical acyclovir (Zovirax®), oral acyclovir 
(400 mg every 12 h) associated with tobramycin eye drops, 
diclofenac sodium ophthalmic solution (Maxilerg®), oral 
acetazolamide (Diamox®)and lubricant (Hyabak®). As 
there was no clinical improvement observed with the initial 
treatment, fungal keratitis was suspected and the treatment 
was then modified to topical pimaricin (5%) and Vigamox® 
every 1 h, and oral ketoconazole (200 mg every 12 h).
Ocular examination showed 20/20 visual acuity 
(VA) in the right eye (RE) without correction, and of 
hand-eye coordination test in the left eye (LE). Normal 
biomicroscopy was observed in the RE, whereas the LE 
presented conjunctival hyperemia (2+/4+) and cornea 
with a central infiltrate measuring 4.3 × 4.0 mm associated 
with small satellite lesions, superimposed epithelial defect 
of 4.3 × 3.5 mm and irregular borders, as well as 2+/4+ 
corneal edema and wide anterior chamber, presence 
of whitish plaque in the lower endothelium measuring 
3.0 × 2.5 mm, 1 mm laminar hypopyon, and diffuse fibrin in 
the endothelium (Figure 1). Moreover, in the LE, increased 
bidigital tonometry was observed, and ultrasound revealed 
no significant changes in the posterior ocular segment.
The patient was admitted to the hospital and corneal 
scraping was performed for bacterioscopy, bacterial culture, 
culture for fungi, bacilloscopy, culture for mycobacteria and 
for direct research techniques1. The patient was prescribed 
pimaricin (5%) every 1 h, acetazolamide (250 mg) 
(Diamox®) every 6 h, and atropine (1%), timolol maleate 
(0.5%), brimonidine tartrate (0.2%), and oral ciprofloxacin 
(750 mg) every 12 h. The laboratory findings showed 
negative results for bacterioscopy and bacilloscopy, positive 
bacteriological culture for Bacillus sp., negative assay and 
culture for fungi, and positive culture for mycobacteria. 
The bacterial colony, described as Bacillus sp according 
to identification by Vitek 2®, was atypical on blood agar 
and therefore, the material was cultivated in Lowestein 
Jensen solid medium, where the growth of characteristic 
mycobacterium colony was confirmed after visualization 
of acid-fast bacilli by Ziehl Neelsen staining. The organism 
was identified as Mycobacterium abscessus subsp. bolletii 
using the hsp65-PRA technique1. 
For the treatment of NTM, the patient was prescribed 
ciprofloxacin hydrochloride (3.5 mg/g) ointment every 6 h 
and oral clarithromycin (500 mg) every 12 h for 18 months, 
fortified vancomycin (2.5%) eye drops for 4 months and 
fortified gentamicin (1.2%) eye drops for 5 months. After 
14 months of treatment, the result of conjunctival lavage 
culture for mycobacteria was negative. The patient showed 
progressive improvement, superior and inferior corneal 
neovascularization, hypopyon regression, reduction of 
infiltrate and edema with leukoma formation, epithelization 
and reduction of intraocular pressure, and 20/40 VA with 
pinhole for the LE at the end of the treatment (Figure 1). 
DISCUSSION
Keratitis caused by NTM is an uncommon disease. 
Girgis et al.2 described an incidence of 36.6% for keratitis 
caused by M. abscessus/M. chelonae with the presence of 
biomaterials (63.1%), eye surgeries (24.1%), and exposure 
to corticosteroids (77%), as risk factors. 
Overall, the M. abcessus complex should be considered 
an agent of infectious keratitis, as well as a pathogen in 
nosocomial and pulmonary infections; the presence of 
Mycobacterium abscessus subsp. bolletii has been reported 
in pulmonary infections in patients with cystic fibrosis6-10. 
Another important characteristic of the M. abcessus complex 
(except for the subspecies massiliense) is the presence of 
macrolide-resistance inducing genes, mainly the erm, which 
can lead to poor treatment response10.
NTM keratitis manifests clinically as an indolent and 
chronic ulceration with the “cracked windshield” appearance 
of the cornea, around the central area of the infiltrate, and 
the lesions caused by these bacteria are important factors 
for diagnosis, but this is not commonly observed2,11. The 
most frequent symptoms of NTM keratitis are nonspecific: 
pain, photophobia, low visual acuity, foreign body sensation 
Figure 1 - Photographs of Mycobacterium abscessus subsp. 
bolletii keratitis clinical evolution: A) acute keratitis with 
presence of hypopyon; B) regression keratitis; C) leukoma with 
neovascularization; D) residual leukoma.
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and irritation11. It can also present keratitis with irregular 
margins and satellite lesions or dendritic epithelial defect 
that simulates fungal or herpetic infections, respectively12. 
Consequently, failure of the initial diagnosis is frequent, as 
in our report, especially if there are no risk factors. However, 
despite the report of appropriate use of personal protective 
equipment, the occupational activity (plumber) might have 
caused exposure to various factors with micro-aerosols that 
contained infectious particles12. 
There are some challenges related to the treatment 
due to poor penetration of the drugs, resistance to most 
conventional antimicrobials and the emergence of resistant 
strains, especially using monotherapy13, and because of 
the lack of consensus on the ideal therapeutic scheme in 
cases of NTM keratitis1,13. In this case, vancomycin and 
gentamicin were used in the fortified eye drops due to the 
fact that these drugs have been used for the last years in the 
treatment of keratitis caused by Mycobacterium abscessus 
subsp. bolletii and others of the M. abcessus complex14,15.
In this context, it is important to highlight that the 
synergism between vancomycin and clarithromycin 
to mycobacterial colonies of the M. abcessus complex 
has already been reported in in vitro studies, showing 
the importance of the association between vancomycin 
and clarithromycin in the same therapeutic regimen16. 
In general, for all M. abcessus complex infections, 
the treatment usually includes aminoglycosides and 
macrolide-based combination therapy, for weeks to 
months, followed by oral antimicrobial therapy4,17,18 and the 
guidelines of the American Thoracic Society and Infectious 
Diseases Society of America. They recommend different 
approaches for the treatment of extrapulmonary M. abcessus 
complex’s infections, in general a total of 4–6 months of 
antibiotic therapy (macrolide-based antibiotic therapy 
such as clarithromycin) with at least 2 weeks of an initial 
combination of parenteral antibiotics is recommended, 
with a high likelihood of cure19,20. As we did not have the 
drug susceptibility test for the macrolide and there are 
different treatment times described in the literature, we 
chose the prolonged treatment (18 months)1. It is important 
to point out that in this case the treatment occurred without 
any adverse reactions and was concluded with excellent 
outcome (cure, Figure 1D), even without the addition of 
corticosteroid.
CONCLUSION
The reported case supports the importance of testing 
for NTM in corneal ulcers that are difficult to control and 
do not respond to initial treatment, even in patients without 
risk factors.
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